[go: up one dir, main page]

MA45481A - Utilisation d'exosomes pour le traitement de maladies - Google Patents

Utilisation d'exosomes pour le traitement de maladies

Info

Publication number
MA45481A
MA45481A MA045481A MA45481A MA45481A MA 45481 A MA45481 A MA 45481A MA 045481 A MA045481 A MA 045481A MA 45481 A MA45481 A MA 45481A MA 45481 A MA45481 A MA 45481A
Authority
MA
Morocco
Prior art keywords
exosomes
diseases
treatment
Prior art date
Application number
MA045481A
Other languages
English (en)
Inventor
Raghu Kalluri
Sonia Melo
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MA45481A publication Critical patent/MA45481A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
    • A23C19/09—Other cheese preparations; Mixtures of cheese with other foodstuffs
    • A23C19/0904—Liquid cheese products, e.g. beverages, sauces
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L23/00—Soups; Sauces; Preparation or treatment thereof
    • A23L23/10—Soup concentrates, e.g. powders or cakes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
    • A23L25/10—Peanut butter
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/60—Salad dressings; Mayonnaise; Ketchup
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/212—Starch; Modified starch; Starch derivatives, e.g. esters or ethers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/231—Pectin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/238—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/25—Exudates, e.g. gum arabic, gum acacia, gum karaya or tragacanth
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/256—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/262—Cellulose; Derivatives thereof, e.g. ethers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L9/00—Puddings; Cream substitutes; Preparation or treatment thereof
    • A23L9/10—Puddings; Dry powder puddings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Pediatric Medicine (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
MA045481A 2015-06-10 2016-06-10 Utilisation d'exosomes pour le traitement de maladies MA45481A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562173838P 2015-06-10 2015-06-10

Publications (1)

Publication Number Publication Date
MA45481A true MA45481A (fr) 2018-04-18

Family

ID=56292904

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045481A MA45481A (fr) 2015-06-10 2016-06-10 Utilisation d'exosomes pour le traitement de maladies

Country Status (14)

Country Link
US (2) US20180177727A1 (fr)
EP (1) EP3307890A1 (fr)
JP (3) JP2018520125A (fr)
KR (1) KR102706532B1 (fr)
CN (2) CN107980004A (fr)
AU (1) AU2016275046B2 (fr)
BR (1) BR112017026467A2 (fr)
CA (1) CA2988585A1 (fr)
EA (1) EA201890006A1 (fr)
HK (1) HK1251257A1 (fr)
IL (1) IL256175B2 (fr)
MA (1) MA45481A (fr)
MX (1) MX2017015962A (fr)
WO (1) WO2016201323A1 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
IL256175B2 (en) 2015-06-10 2024-10-01 Univ Texas Using exosomes to treat the disease
CN106727548B (zh) * 2016-12-23 2020-08-21 蒋培都 烷基吡啶类化合物在制备诱导细胞自噬药物的应用及方法
US11319360B2 (en) 2016-12-29 2022-05-03 Korea Institute Of Science And Technology Exosome-based anticancer agent
CN108066361A (zh) * 2017-01-23 2018-05-25 广州中科蓝华生物科技有限公司 一种外泌体，其制备方法及其在制备抗肿瘤的药物或者制剂中的用途
WO2018165631A1 (fr) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Vaccin contre le cancer
AU2018254498B2 (en) * 2017-04-19 2023-08-03 Figene, Llc Stimulation of angiogenesis by fibroblast derived exosomes
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
KR20200044806A (ko) * 2017-07-28 2020-04-29 내셔널 유니버시티 오브 싱가포르 변형된 유령 세포를 포함하는 생물분자 복합체
TR201716062A2 (tr) * 2017-10-18 2019-05-21 Tuerkiye Bilimsel Ve Teknolojik Arastirma Kurumu Tuebitak Bi̇r eksozomal terapöti̇k taşiyici üreti̇m yöntemi̇ ve bu yönteme uygun bi̇r şeki̇lde elde edi̇len bi̇r eksozomal terapöti̇k taşiyici
KR20200098639A (ko) * 2017-12-15 2020-08-20 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 엑소좀 관련 유전자 편집을 이용한 암 치료 방법 및 조성물
EP3505187A1 (fr) * 2017-12-27 2019-07-03 Tzu Chi University Administration d'un agent dans des cellules autophagiques et apoptotiques par des vésicules ayant une protéine exprimée sur leur surface
JP7253762B2 (ja) * 2017-12-27 2023-04-07 慈濟大學 タンパク質を表面に発現させた小胞によるオートファジー細胞およびアポトーシス細胞への薬剤送達
WO2019157535A1 (fr) * 2018-02-12 2019-08-15 Codiak Biosciences, Inc. Procédés et compositions pour la polarisation des macrophages
WO2019169141A1 (fr) * 2018-02-28 2019-09-06 Lester Smith Medical Research Institute Production et utilisation de vésicules extracellulaires
US20210007988A1 (en) * 2018-03-12 2021-01-14 Board Of Regents, The University Of Texas System Immuno-exosomes and methods of use thereof
CN108486060B (zh) * 2018-03-12 2021-09-14 绍兴优铭生物科技有限公司 一种用于治疗肿瘤的外泌体及其制备方法和应用
US12241888B2 (en) 2018-03-14 2025-03-04 Children's Medical Center Corporation Platform for assessment of the transcytosis of extracellular vesicles across endothelial barriers and uses thereof
CN112118866A (zh) * 2018-03-23 2020-12-22 科迪亚克生物科学公司 包含sting激动剂的细胞外囊泡
AU2019242912B2 (en) 2018-03-28 2025-07-17 Board Of Regents, The University Of Texas System Identification of epigenetic alterations in DNA isolated from exosomes
KR20200136978A (ko) * 2018-03-28 2020-12-08 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 치료제의 표적화된 전달을 위한 엑소좀의 용도
EP3773506A4 (fr) * 2018-03-29 2021-12-22 Technion Research & Development Foundation Limited Vésicules comprenant un inhibiteur de pten et leurs utilisations
WO2019199803A1 (fr) * 2018-04-09 2019-10-17 Board Of Regents, The University Of Texas System Ciblage thérapeutique d'oncogènes à l'aide d'exosomes
EP3781131A4 (fr) * 2018-04-19 2022-06-01 Board of Regents, The University of Texas System Modulation thérapeutique de suppresseurs tumoraux à l'aide d'exosomes
CN108587998B (zh) * 2018-05-17 2021-05-18 浙江大学 一种外泌体、外泌体的制备方法及其在制备皮肤浅表性肿瘤的药物中的应用
CN108635372A (zh) * 2018-05-17 2018-10-12 广东芙金干细胞再生医学有限公司 一种人间充质干细胞源外泌体的生物制剂的制备方法
CN108866058B (zh) * 2018-07-12 2021-09-10 苏州吉玛基因股份有限公司 靶向KRAS的siRNA及其在制备胰腺癌治疗药物中的应用
CN108865976B (zh) * 2018-07-19 2022-06-28 复旦大学附属中山医院 一种离散汲取收集外泌体(exosome)的方法及试剂
CN108815187A (zh) * 2018-07-20 2018-11-16 深圳市第二人民医院 一种包含人关节液外泌体的制剂及其使用方法
EP3823995A4 (fr) * 2018-08-01 2022-05-04 The Regents of the University of Colorado, a body corporate Vésicules gectosomes sécrétés fusogènes thérapeutiques de conception programmable pour l'administration de macromolécules et la modification du génome
JP7480143B2 (ja) * 2018-08-10 2024-05-09 オムニスピラント リミテッド 吸入用細胞外小胞
CN110960688A (zh) * 2018-09-30 2020-04-07 复旦大学 用于提高胰腺癌疗效的低毒仿生化纳米系统及制备方法
US20210395721A1 (en) 2018-10-24 2021-12-23 Codiak Biosciences, Inc. Methods to improve potency of electroporation
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
US20220397580A1 (en) * 2019-01-31 2022-12-15 National University Of Singapore Method of detecting a neurodegenerative disease
JP2022519718A (ja) * 2019-02-08 2022-03-24 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 加齢および加齢性臓器不全に関連する疾患の処置のためのテロメラーゼ含有エキソソーム
WO2020198626A1 (fr) * 2019-03-27 2020-10-01 University Of Georgia Research Foundation, Inc. Procédés de fabrication de vésicules ciblées, et compositions ainsi fabriquées
CN110004110A (zh) * 2019-04-09 2019-07-12 江苏省人民医院（南京医科大学第一附属医院） 一种肠道外泌体提取方法
WO2020214842A1 (fr) 2019-04-17 2020-10-22 The Broad Institute, Inc. Éditeurs de base d'adénine présentant des effets hors cible réduits
CA3137525A1 (fr) * 2019-04-23 2020-10-29 Children's Medical Center Corporation Utilisation d'inhibiteurs de la gtpase rab7 (rab7) pour augmenter la permeabilite de la barriere hemato-encephalique (bhe)
JP2022536364A (ja) 2019-06-13 2022-08-15 ザ ジェネラル ホスピタル コーポレイション 操作されたヒト内在性ウイルス様粒子および細胞への送達のためのその使用方法
WO2021026353A2 (fr) * 2019-08-06 2021-02-11 Ohio State Innovation Foundation Vésicules extracellulaires thérapeutiques
EP4470619A3 (fr) * 2019-08-14 2025-04-23 Lonza Sales AG Constructions de vésicule extracellulaire-aso ciblant stat6
US20230002764A1 (en) * 2019-08-14 2023-01-05 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting cebp/beta
CN114641570A (zh) * 2019-08-14 2022-06-17 科迪亚克生物科学公司 具有靶向kras的反义寡核苷酸的细胞外囊泡
CN114173807B (zh) * 2019-09-02 2024-03-19 庆北大学校产学协力团 包含il-2表面表达-细胞外囊泡作为活性成分的用于预防或治疗癌症的组合物
CN112823811B (zh) * 2019-11-18 2022-07-29 深圳先进技术研究院 一种跨越血脑屏障和特异性靶向脑胶质瘤治疗药物的投递系统的制备方法
JP7761562B2 (ja) * 2019-11-27 2025-10-28 ノバリック ゲーエムベーハー 非水性溶媒で懸濁されたタンパク質粒子を含む懸濁製剤
EP4069205A4 (fr) * 2019-12-05 2024-01-10 Board of Regents, The University of Texas System Thérapie à base d'exosomes pour la fibrose du foie et d'autres maladies associées à la fibrose
CN112972702A (zh) * 2019-12-17 2021-06-18 南京大学 用于治疗耐药菌感染的外泌体制剂
CA3168806A1 (fr) * 2020-01-22 2021-07-29 Agex Therapeutics, Inc. Exosomes therapeutiques et leur procede de production
CN111358957B (zh) * 2020-03-06 2024-03-26 西安组织工程与再生医学研究所 磁性纳米颗粒
CN114164276B (zh) * 2020-03-30 2022-05-20 中国医学科学院肿瘤医院 用于肺癌诊断的试剂盒、装置及方法
EP4100530A4 (fr) * 2020-04-07 2024-05-22 The University of North Carolina at Chapel Hill Procédés et compositions utilisant l'interférence par l'arn et des oligonucléotides antisens pour l'inhibition de kras
WO2022020800A2 (fr) 2020-07-24 2022-01-27 The General Hospital Corporation Pseudo-particules virales améliorées et leurs méthodes d'utilisation pour l'administration à des cellules
WO2022120366A1 (fr) * 2020-12-02 2022-06-09 Northwestern University Méthodes et compositions pour le traitement d'une infection à coronavirus, y compris au sars-cov 2
EP4277933A4 (fr) 2021-01-14 2024-12-11 Senti Biosciences, Inc. Régulation de charge utile sécrétable
CN113144222B (zh) * 2021-04-14 2023-05-23 台州学院 外泌体用于防止脑型疟疾发生的实验方法
IT202100021779A1 (it) * 2021-08-11 2023-02-11 Plasfer S R L Piastrine trasfettate con sirna e loro usi terapeutici
KR20240082391A (ko) * 2021-10-14 2024-06-10 론자 세일즈 아게 세포외 소포 생산을 위한 변형된 생산자 세포
CN115990261B (zh) * 2021-10-20 2024-01-05 光武惠文生物科技(北京)有限公司 外泌体冻干粉针剂或外泌体液体制剂的保护剂
EP4441074A2 (fr) 2021-12-03 2024-10-09 The Broad Institute, Inc. Compositions et méthodes pour administration in vivo efficace
WO2023225572A2 (fr) 2022-05-17 2023-11-23 Nvelop Therapeutics, Inc. Compositions et méthodes pour administration in vivo efficace
WO2024039896A1 (fr) * 2022-08-19 2024-02-22 Northeastern University Exosomes modifiés par un peptide cationique/protéine pour des applications dans l'administration de médicament
CN115895998A (zh) * 2022-11-16 2023-04-04 大连理工大学 一种不同植物组织来源的完整外泌体的分离方法
AU2024307229A1 (en) * 2023-06-28 2025-10-09 Exollence Co., Ltd. Pharmaceutical composition for preventing or treating cancer comprising sirna as active ingredient
CN117643575A (zh) * 2023-11-03 2024-03-05 中山大学 一种纳米材料及其制备方法和应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US20030064949A1 (en) 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6391582B2 (en) 1998-08-14 2002-05-21 Rigel Pharmaceuticlas, Inc. Shuttle vectors
FR2785543B1 (fr) 1998-11-05 2003-02-28 Inst Nat Sante Rech Med Exosomes modifies et utilisations
GB9927320D0 (en) 1999-11-18 2000-01-12 Chiron Spa Exosome separation
US6812023B1 (en) 2000-04-27 2004-11-02 Anosys, Inc. Methods of producing membrane vesicles
AU2001275423B2 (en) 2000-06-09 2007-01-11 Regulon, Inc. Encapsulation of polynucleotides and drugs into targeted liposomes
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
WO2002082904A2 (fr) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Traitement soignant ou retardant l'installation de la cecite
US20050159378A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
FR2827872A1 (fr) 2001-07-30 2003-01-31 Roussy Inst Gustave Vesicules membranaires de fluide biologique preleve in vivo, leur preparation et utilisation dans la stimulation d'une reponse immunitaire
EP1417229B1 (fr) 2001-08-17 2011-06-15 Exothera L.L.C. Procedes et composes pour le ciblage de proteines vers des exosomes
WO2003044166A2 (fr) 2001-11-15 2003-05-30 The Regents Of The University Of California Procedes et compositions permettant de reguler l'expression genique par la modulation de la rotation de l'arnm
US7405292B2 (en) 2002-02-19 2008-07-29 The Children's Hospital Of Philadelphia Cellular genes regulated by HIV-1 infection and methods of use thereof
US7803906B2 (en) 2002-03-22 2010-09-28 Gene Signal International Sa Composition comprising an angiogenesis related protein
KR100519384B1 (ko) 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
WO2005121369A2 (fr) 2004-06-02 2005-12-22 Sourcepharm, Inc. Microvesicules contenant de l'arn et methodes associees
GB0416120D0 (en) 2004-07-19 2004-08-18 Health Prot Agency Stable compositions containing OMV's
JP5096369B2 (ja) 2005-12-20 2012-12-12 ブリストル−マイヤーズ スクイブ カンパニー 組成物および組成物の製造方法
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
WO2009015357A1 (fr) 2007-07-25 2009-01-29 University Of Louisville Research Foundation, Inc. Micro arn associé à l'exosome en tant que marqueur de diagnostic
US9186405B2 (en) 2007-08-16 2015-11-17 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
ES2936256T3 (es) 2008-02-01 2023-03-15 Massachusetts Gen Hospital Uso de microvesículas en el diagnóstico, y pronóstico de enfermedades y afecciones médicas
EP2799557B1 (fr) 2008-02-28 2016-09-07 The Ohio State University Research Foundation Antagonistes de miR-32 pour augmenter la sensibilité des cellules cancéreuses de la prostate à l'apoptose
WO2009147519A1 (fr) 2008-06-06 2009-12-10 Centre National De La Recherche Scientifique - Cnrs- Utilisation du système endolysosomal et de vésicules sécrétées (de type exosome) dans des traitements et des diagnostics basés sur des petits arn et l’étude expérimentale de petits arn
CN102301002A (zh) 2008-11-12 2011-12-28 卡里斯生命科学卢森堡控股有限责任公司 使用外来体来确定表现型的方法和系统
US20130053426A1 (en) 2009-04-17 2013-02-28 Yiqi Seow Composition For Delivery Of Genetic Material
CN102596177B (zh) 2009-07-01 2014-05-28 阿昂梅迪克斯公司 来源于有核哺乳动物细胞的微囊泡及其应用
US20120315324A1 (en) * 2010-02-05 2012-12-13 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
WO2011126010A1 (fr) * 2010-04-06 2011-10-13 三菱化学株式会社 Peptide pénétrant dans les cellules spécifique aux cellules cancéreuses et son utilisation
CA2795776A1 (fr) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarqueurs circulants pour une maladie
EP2561072A4 (fr) 2010-04-20 2016-04-06 Univ Florida Nanozymes, procédés de production de nanozymes, et procédés d'utilisation de nanozymes
US9376679B2 (en) 2010-05-26 2016-06-28 Micromedmark Biotech Co. Ltd. Microvesicles carrying small interfering RNAs, preparation methods and uses thereof
EP2578236B1 (fr) 2010-05-26 2016-03-30 Micromedmark Biotech Co., Ltd Préparation de complexes microvésicule-sirna et utilisation desdits complexes dans le traitement du sida
CN101869715A (zh) 2010-05-26 2010-10-27 江苏命码生物科技有限公司 载有干扰核糖核酸的细胞微粒子、其制备方法及其应用
WO2012020307A2 (fr) 2010-08-13 2012-02-16 The University Court Of The University Of Glasgow Utilisations thérapeutiques de microvésicules et de microarn associés
AU2011316477A1 (en) 2010-10-11 2013-05-02 Medsaic Pty Ltd Assay for disease detection
CN103459613A (zh) 2011-01-31 2013-12-18 艾索特里克斯遗传实验室有限责任公司 使用结合分子富集微粒或核酸的方法
CA2829586C (fr) 2011-03-11 2021-03-02 Children's Medical Center Corporation Procedes et compositions associes aux exosomes de cellules souches mesenchymateuses
WO2012131733A2 (fr) 2011-03-31 2012-10-04 Godavari Biorefineries Limited Compositions de milieu, procédé d'initiation et d'enrichissement de cultures de cellules souches et/ou de cellules de type cellules souches cancéreuses
WO2013052167A2 (fr) * 2011-06-02 2013-04-11 The Regents Of The University Of California Nanoparticules encapsulées dans une membrane et leur procédé d'utilisation
AU2012294458A1 (en) 2011-08-08 2014-02-27 Caris Life Sciences Switzerland Holdings Gmbh Biomarker compositions and methods
GB201121070D0 (en) * 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
US9777042B2 (en) 2011-12-15 2017-10-03 Morehouse School Of Medicine Method of purifying HIV/SIV Nef from exosomal fusion proteins
WO2013138427A1 (fr) 2012-03-16 2013-09-19 The General Hospital Corporation Administration de molécules thérapeutiques médiée par des microvésicules
US20130273544A1 (en) 2012-04-17 2013-10-17 Life Technologies Corporation Methods and compositions for exosome isolation
KR20150006477A (ko) * 2012-05-09 2015-01-16 그래댈리스, 인코포레이티드 단일-뉴클레오타이드 ｋｒａｓ 돌연변이에 특이적인 이-기능성 짧은-헤어핀 ｒｎａ (ｂｉ-ｓｈｒｎａ)
US9076953B2 (en) * 2012-05-09 2015-07-07 Qualcomm Incorporated Spin transistors employing a piezoelectric layer and related memory, memory systems, and methods
WO2013185032A1 (fr) * 2012-06-07 2013-12-12 President And Fellows Of Harvard College Produits nanothérapeutiques pour le ciblage de médicament
JP6391582B2 (ja) 2012-11-13 2018-09-19 コディアック バイオサイエンシズ インコーポレイテッド 治療剤の送達方法
AU2013347838A1 (en) 2012-11-26 2015-06-11 Caris Life Sciences Switzerland Holdings Gmbh Biomarker compositions and methods
JP2016505256A (ja) 2012-12-12 2016-02-25 ザ・ブロード・インスティテュート・インコーポレイテッ 配列操作のためのＣＲＩＳＰＲ−Ｃａｓ成分系、方法および組成物
BR112015023275B1 (pt) 2013-03-15 2022-06-21 Board Of Regents, The University Of Texas System Método in vitro de detecção de biomarcador de câncer
JP6137894B2 (ja) * 2013-03-22 2017-05-31 国立大学法人京都大学 リポソーム−エキソソームハイブリッドベシクル及びその調製法
SG11201508433TA (en) * 2013-04-12 2015-11-27 Andaloussi Samir El Therapeutic delivery vesicles
KR20150043937A (ko) 2013-10-15 2015-04-23 삼성전자주식회사 개체의 간암 진단용 조성물, 개체의 간암 진단하는 방법 및 개체의 간암 진단에 필요한 정보를 얻는 방법
HRP20192131T1 (hr) 2013-12-04 2020-02-21 Board Of Regents, The University Of Texas System Metoda za izolaciju egzosoma izvedenih iz stanica karcinoma
SG10201804977UA (en) 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Targeting Disorders and Diseases Using Particle Delivery Components
CN116731958A (zh) 2014-10-09 2023-09-12 细胞结构公司 胎盘来源的贴壁细胞外泌体及其用途
US20160113966A1 (en) 2014-10-27 2016-04-28 Hans Klingemann Composition and methods of culture supernatant of khyg-1 cells
WO2016077639A2 (fr) 2014-11-12 2016-05-19 VL27, Inc. Thérapies nanovésiculaires
WO2018062973A1 (fr) * 2016-09-30 2018-04-05 Cellex Life Sciences, Incorporated Compositions contenant un exosome chargé d'une protéine, et procédés de préparation et d'administration correspondants
IL256175B2 (en) 2015-06-10 2024-10-01 Univ Texas Using exosomes to treat the disease
WO2017072744A1 (fr) 2015-10-30 2017-05-04 National Institute Of Infectious Diseases And Vaccinology, National Health Research Institutes Lignées cellulaires mdck en suspension dans des milieux sans sérum chimiquement définis pour la production de vaccins
EP3430024A4 (fr) 2016-03-15 2019-11-13 Codiak BioSciences, Inc. Vésicules membranaires thérapeutiques
US20210290556A1 (en) 2016-08-22 2021-09-23 Codiak Biosciences, Inc. Methods of suppressing delivery of exosomes to liver and spleen

Also Published As

Publication number Publication date
CA2988585A1 (fr) 2016-12-15
AU2016275046B2 (en) 2022-07-28
US20180177727A1 (en) 2018-06-28
MX2017015962A (es) 2018-07-06
NZ738149A (en) 2024-02-23
JP2018520125A (ja) 2018-07-26
JP2021107463A (ja) 2021-07-29
AU2016275046A1 (en) 2018-01-04
JP2024023853A (ja) 2024-02-21
CN113694075A (zh) 2021-11-26
EA201890006A1 (ru) 2018-05-31
IL256175B2 (en) 2024-10-01
WO2016201323A1 (fr) 2016-12-15
US20190117570A1 (en) 2019-04-25
BR112017026467A2 (pt) 2018-09-11
JP7620968B2 (ja) 2025-01-24
US10959952B2 (en) 2021-03-30
CN107980004A (zh) 2018-05-01
IL256175B1 (en) 2024-06-01
EP3307890A1 (fr) 2018-04-18
IL256175A (en) 2018-02-28
HK1251257A1 (zh) 2019-01-25
KR20180017119A (ko) 2018-02-20
KR102706532B1 (ko) 2024-09-19

Similar Documents

Publication Publication Date Title
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA45192A (fr) Traitement d'association
ME03314B (fr) Thérapie basée sur l'arnm pour le traitement des maladies oculaires
EP3503890A4 (fr) Utilisation de la pridopidine pour le traitement des dystonies
EP3288592A4 (fr) Utilisation de cannabidiol pour le traitement de spasmes infantiles
MA45089A (fr) Utilisation d'indazoles 2-substitués pour le traitement et la prophylaxie de maladies auto-immunes
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3380200A4 (fr) Compositions pour le traitement des cheveux
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
EP3512517A4 (fr) Utilisation de pridopidine pour le traitement de l'anxiété et de la dépression
EP3380063A4 (fr) Compositions pour le traitement des cheveux
EP3344325A4 (fr) Administration locale de médicaments pour le traitement de l'asthme
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
EP3512506A4 (fr) Utilisation de la pridopidine pour le traitement du syndrome de rett
EP3347032A4 (fr) Traitement de l'ascite
EP3349793A4 (fr) Anti-s100a8 pour le traitement de la leucémie
EP3413898A4 (fr) Utilisation de tréhalose pour le traitement de maladies neurologiques
EP3395341A4 (fr) Composition pour le traitement de maladies neuromotrices et son utilisation